279 related articles for article (PubMed ID: 23545914)
1. Efficacy of topical 4% Quassia amara gel in facial seborrheic dermatitis:a randomized, double-blind, comparative study.
Diehl C; Ferrari A
J Drugs Dermatol; 2013 Mar; 12(3):312-5. PubMed ID: 23545914
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and tolerance of a topical gel with 4% quassia extract in the treatment of rosacea.
Ferrari A; Diehl C
J Clin Pharmacol; 2012 Jan; 52(1):84-8. PubMed ID: 21343346
[TBL] [Abstract][Full Text] [Related]
3. Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study.
Seckin D; Gurbuz O; Akin O
J Eur Acad Dermatol Venereol; 2007 Mar; 21(3):345-50. PubMed ID: 17309456
[TBL] [Abstract][Full Text] [Related]
4. A novel cosmetic antifungal/anti-inflammatory topical gel for the treatment of mild to moderate seborrheic dermatitis of the face: an open-label trial utilizing clinical evaluation and erythema-directed digital photography.
Dall' Oglio F; Tedeschi A; Fusto CM; Lacarrubba F; Dinotta F; Micali G
G Ital Dermatol Venereol; 2017 Oct; 152(5):436-440. PubMed ID: 28121079
[TBL] [Abstract][Full Text] [Related]
5. Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review.
Gupta AK; Versteeg SG
Am J Clin Dermatol; 2017 Apr; 18(2):193-213. PubMed ID: 27804089
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis.
Ratnavel RC; Squire RA; Boorman GC
J Dermatolog Treat; 2007; 18(2):88-96. PubMed ID: 17520465
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial.
Elewski B; Ling MR; Phillips TJ
J Drugs Dermatol; 2006; 5(7):646-50. PubMed ID: 16865870
[TBL] [Abstract][Full Text] [Related]
8. Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis.
Chosidow O; Maurette C; Dupuy P
Dermatology; 2003; 206(3):233-40. PubMed ID: 12673081
[TBL] [Abstract][Full Text] [Related]
9. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face.
Elewski B
Clin Dermatol; 2009; 27(6 Suppl):S48-53. PubMed ID: 19878781
[TBL] [Abstract][Full Text] [Related]
10. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis.
Squire RA; Goode K
J Dermatolog Treat; 2002 Jun; 13(2):51-60. PubMed ID: 12060502
[TBL] [Abstract][Full Text] [Related]
11. An open-label pilot study of naftifine 1% gel in the treatment of seborrheic dermatitis of the scalp.
Gold MH; Bridges T; Avakian EV; Plaum S; Fleischer AB; Hardas B
J Drugs Dermatol; 2012 Apr; 11(4):514-8. PubMed ID: 22453590
[TBL] [Abstract][Full Text] [Related]
12. Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage.
Abeck D;
Int J Dermatol; 2004 Jul; 43 Suppl 1():13-6. PubMed ID: 15271195
[TBL] [Abstract][Full Text] [Related]
13. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis.
Warshaw EM; Wohlhuter RJ; Liu A; Zeller SA; Wenner RA; Bowers S; Schultz JC; Katz HI; McCormick CL; Parneix-Spake A
J Am Acad Dermatol; 2007 Aug; 57(2):257-64. PubMed ID: 17188780
[TBL] [Abstract][Full Text] [Related]
14. Ciclopiroxolamine cream for treating seborrheic dermatitis: a double-blind parallel group comparison.
Unholzer A; Varigos G; Nicholls D; Schinzel S; Nietsch KH; Ulbricht H; Korting HC
Infection; 2002 Dec; 30(6):373-6. PubMed ID: 12478328
[TBL] [Abstract][Full Text] [Related]
15. A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis.
Piérard-Franchimont C; Piérard GE
Dermatology; 2002; 204(4):344-7. PubMed ID: 12077544
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial.
Lebwohl M; Plott T
Int J Dermatol; 2004 Jul; 43 Suppl 1():17-20. PubMed ID: 15271196
[TBL] [Abstract][Full Text] [Related]
17. Ciclopirox gel for seborrheic dermatitis of the scalp.
Aly R; Katz HI; Kempers SE; Lookingbill DP; Lowe N; Menter A; Morman M; Savin RC; Wortzman M
Int J Dermatol; 2003 Sep; 42 Suppl 1():19-22. PubMed ID: 12895183
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: results of a randomized, double-blind, vehicle-controlled trial.
Altmeyer P; Hoffmann K;
Int J Dermatol; 2004 Jul; 43 Suppl 1():9-12. PubMed ID: 15271194
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of a new ciclopiroxolamine/zinc pyrithione shampoo in scalp seborrheic dermatitis treatment.
Lorette G; Ermosilla V
Eur J Dermatol; 2006; 16(5):558-64. PubMed ID: 17101479
[TBL] [Abstract][Full Text] [Related]
20. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions.
Elewski BE; Abramovits W; Kempers S; Schlessinger J; Rosen T; Gupta AK; Abraham S; Rowell R
J Drugs Dermatol; 2007 Oct; 6(10):1001-8. PubMed ID: 17966177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
